---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-26-000072"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2026-07-07T21:05:03+00:00"
generated_at: "2026-07-07T21:06:03.847524+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Praxis Precision Medicines partners with Remagine Labs for transdermal patch of ulixacaltamide

## Summary
- Collaboration to develop iontophoretic transdermal patch for ulixacaltamide for essential tremor.
- Remagine's platform enables precise, multi-day active transdermal dosing.
- Praxis made an equity investment in Remagine to support program advancement.
- Transdermal option intended to broaden patient population and strengthen competitive positioning.

## SEC filing metadata
- accession: 0001689548-26-000072
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2026-07-07T21:05:03+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000072/0001689548-26-000072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000072/prax-20260707.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-26-000072
- JSON: https://secwatch.observer/filing/0001689548-26-000072.json
- Plain text: https://secwatch.observer/filing/0001689548-26-000072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.